Stocks and Investing
Stocks and Investing
Wed, March 8, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Tue, March 7, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Anupam Rama Maintained (BBIO) at Buy with Increased Target to $23 on, Mar 7th, 2023
Anupam Rama of JP Morgan, Maintained "BridgeBio Pharma, Inc." (BBIO) at Buy with Increased Target from $18 to $23 on, Mar 7th, 2023.
Anupam has made no other calls on BBIO in the last 4 months.
There are 2 other peers that have a rating on BBIO. Out of the 2 peers that are also analyzing BBIO, 0 agree with Anupam's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Anupam
- Tyler Van Buren of "Cowen & Co." Initiated at Buy on, Monday, February 6th, 2023
- Mani Foroohar of "SVB Leerink" Maintained at Buy with Decreased Target to $19 on, Monday, January 23rd, 2023
Contributing Sources